Corrona is a prospective observational registry founded in 2002 that collects data from patients and physicians about rheumatoid arthritis, psoriatic arthritis, other spondyloarthritis, and psoriasis. Here, we summarize the significant findings derived from the psoriatic arthritis Corrona database and describe future goals for Corrona's application in psoriasis.
HarroldL.R., ReedG.W., ShewadeA.. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry.J Rheumatol.2015 Jul; 42(7): 1090–8.
4.
KalbR.E., FiorentinoD.F., LebwohlM.G.. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).JAMA Dermatol.2015 Sep; 151(9): 961–9.
5.
KremerJ.M.. The CORRONA database.Autoimmun Rev.2006; 5: 46–54.
6.
BoydT., KavanaughA.. Novel Treatment Concepts in Psoriatic Arthritis.Rheum Dis Clin North Am.2015 Nov; 41(4): 739–54.
7.
van de KerkhofP.C., NestleF.. No Title. In: BologniaJ., JorizzoJ., SchafferJ., editors. Dermatology.3rd ed.Elsevier; 2012. p. 135–55.
8.
FredianiB., AllegriA., FalsettiP.. Bone mineral density in patients with psoriatic arthritis.J Rheumatol.2001 Jan; 28(1): 138–43.
9.
AnandarajahA.P., SchwarzE.M., TottermanS.. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis.Ann Rheum Dis.2008 Mar; 67(3): 296–301.
10.
AnandarajahA.P., PengC., GreenbergJ.D., RitchlinC.T.. The association between focal bone loss (erosions) and generalized bone loss (osteoporosis) in rheumatoid arthritis.Arthritis Rheum.2009; 60(S10): S373.
11.
WrightV.. Psoriatic arthritis. A comparative radiographic study of rheumatoid arthritis and arthritis associated with psoriasis.Ann Rheum Dis.1961 Jun; 20: 123–32.
12.
KaneD., StaffordL., BresnihanB., FitzGeraldO.. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.Rheumatology (Oxford).2003 Dec; 42(12): 1460–8.
13.
PadhiT., Garima. Metabolic syndrome and skin: psoriasis and beyond.Indian J Dermatol.2013 Jul; 58(4): 299–305.
14.
LabitiganM., Bahče-AltuntasA., KremerJ.M.. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis.Arthritis Care Res (Hoboken).2014; 66(4): 600–7.
15.
BailinP.L., TindallJ.P., RoenigkH.H., HoganM.D.. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis.JAMA.1975 Apr 28; 232(4): 359–62.
16.
NyforsA., JensenH.. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study.Dermatologica.1983 Jan; 167(5): 260–1.
17.
GrossR.L., Schwartzman-MorrisJ.S., KrathenM.. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.Arthritis Rheumatol.2014; 66(6): 1472–81.
18.
ReddyS.M., AnandarajahA.P., FisherM.C.. Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry.J Rheumatol.2010 Dec;37(12): 2566–72.
19.
SotoudehmaneshR., AnvariB., AkhlaghiM., ShahraeeniS., KolahdoozanS.. Methotrexate hepatotoxicity in patients with rheumatoid arthritis.Middle East J Dig Dis.2010 Sep;2(2): 104–9.
20.
CurtisJ.R., BeukelmanT., OnofreiA.. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.Ann Rheum Dis.2009 Jan 15; 69(01): 43–7.
21.
RyanC., KormanN.J., GelfandJ.M.. Research gaps in psoriasis: opportunities for future studies.J Am Acad Dermatol.2014 Jan; 70(1): 146–67.
22.
GreenbergJ.D., KremerJ.M., CurtisJ.R.. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.Ann Rheum Dis.2011; 70(4): 576–82.
